Eli Lilly (LLY): FY25 Q3 earnings call, Oct 30, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Oct 30, 2025 earnings call (FY25 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
26 matches for “Phase 3”; 5 quoted, at least 25 words apart.
…The EU approved Kisunla for early symptomatic Alzheimer's disease. Positive results from Phase III trial of Jaypirca in treatment of naive CLL. Positive overall survival…
…driven by continued investments in our portfolio. We have initiated 16 new Phase III programs since the start of 2024 and continue to advance our…
…to build momentum both in the marketplace and with new data from Phase III trials. Dan will talk more about this later during the R&D…
…health. Since our last call, we announced results from 4 additional positive Phase III trials for orforglipron. Of note, one of those trials was attained…
…benefit as an add-on therapy to titrated insulin glargine. With 4 positive Phase III diabetes trials now completed, we believe orforglipron has the potential to…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-10-30:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-10-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP